STOCKSCREENR

ANAB

NASDAQ

AnaptysBio, Inc.

$65.73+3.39(+5.44%)Mkt Cap: $2.83B

Key Stats

Market Cap

$2.83B

P/E Ratio

-142.89

EPS

$-0.46

Dividend Yield

0.00%

52-Week Range

$11.40 — $71.67

Volume

432.11K

Avg Volume

863.38K

Beta

0.41

Price Alerts for ANAB

Get alerted when ANAB hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

-142.89

Forward P/E

—

PEG Ratio

-1.53

P/S (TTM)

8.03

P/B (TTM)

48.95

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

18.14%

ROA (TTM)

-0.04%

ROIC

—

Gross Margin

0.99%

Operating Margin

0.20%

Net Margin

—

Debt/Equity

7.81

Current Ratio

9.07

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-0.45%

EPS Growth (5Y)

-0.49%

Sales Growth (3Y)

+1.38%

Sales Growth (5Y)

+2.47%

EPS Est (This Year)

$-3.94

EPS Est (Next Year)

$-3.25

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$11.21

Analyst Consensus

Price Target Range

$50.00$66.00$140.00
LowMedianHigh

Consensus Target: $73.71(12.1% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

-48324

Outstanding Shares

28.75M

Float

26.77M

Free Float %

93.13%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2017-01-26

Employees

136

CEO

Daniel R. Faga

Index Membership

—

Website

https://www.anaptysbio.com

AnaptysBio, Inc. (ANAB) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $2.83B, a P/E ratio of -142.89, ANAB is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare ANAB against other stocks using dozens of fundamental and technical filters.

Similar Stocks

CBIO

Crescent Biopharma, Inc.

$22.37

+6.83%

$616.45M

NUVL

Nuvalent, Inc.

$100.28

+1.19%

$7.34B

ZBIO

Zenas BioPharma, Inc.

$19.32

+10.09%

$862.50M

GHRS

GH Research PLC

$20.53

+7.15%

$1.27B

BHVN

Biohaven Ltd.

$9.59

+4.24%

$1.02B

ABUS

Arbutus Biopharma Corporation

$4.20

+1.69%

$827.15M

Frequently Asked Questions

What is AnaptysBio, Inc.'s P/E ratio?

AnaptysBio, Inc. (ANAB) has a trailing twelve-month (TTM) P/E ratio of -142.89. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does AnaptysBio, Inc. pay a dividend?

No, AnaptysBio, Inc. (ANAB) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is AnaptysBio, Inc.'s market cap?

AnaptysBio, Inc. (ANAB) has a market capitalization of $2.83 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.